Establishing a standardized therapeutic testing protocol for spinal muscular atrophy

Li Kai Tsai, Ming Shung Tsai, Tzer Bin Lin, Wuh Liang Hwu, Hung Li

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Several mice models have been created for spinal muscular atrophy (SMA); however, there is still no standard preclinical testing system for the disease. We previously generated type III-specific SMA model mice, which might be suitable for use as a preclinical therapeutic testing system for SMA. To establish such a system and test its applicability, we first created a testing protocol and then applied it as a means to investigate the use of valproic acid (VPA) as a possible treatment for SMA. These SMA mice revealed tail/ear/foot deformity, muscle atrophy, poorer motor performances, smaller compound muscle action potential and lower spinal motoneuron density at the age of 9 to 12 months in comparison with age-matched wild-type littermate mice. In addition, VPA attenuates motoneuron death, increases spinal SMN protein level and partially normalizes motor function in SMA mice. These results suggest that the testing protocol developed here is well suited for use as a standardized preclinical therapeutic testing system for SMA.

Original languageEnglish
Pages (from-to)286-295
Number of pages10
JournalNeurobiology of Disease
Volume24
Issue number2
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Fingerprint

Spinal Muscular Atrophy
Valproic Acid
Motor Neurons
Therapeutics
Spinal Muscular Atrophies of Childhood
Foot Deformities
Muscular Atrophy
Action Potentials
Ear
Tail
Muscles
Proteins

Keywords

  • Animal model
  • Motoneuron disease
  • Neuronal degeneration
  • Phenotype
  • Spinal cord
  • Spinal muscular atrophy
  • Valproic acid

ASJC Scopus subject areas

  • Neurology

Cite this

Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. / Tsai, Li Kai; Tsai, Ming Shung; Lin, Tzer Bin; Hwu, Wuh Liang; Li, Hung.

In: Neurobiology of Disease, Vol. 24, No. 2, 11.2006, p. 286-295.

Research output: Contribution to journalArticle

Tsai, Li Kai ; Tsai, Ming Shung ; Lin, Tzer Bin ; Hwu, Wuh Liang ; Li, Hung. / Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. In: Neurobiology of Disease. 2006 ; Vol. 24, No. 2. pp. 286-295.
@article{35b94de0b4b142c88f4d75214760236d,
title = "Establishing a standardized therapeutic testing protocol for spinal muscular atrophy",
abstract = "Several mice models have been created for spinal muscular atrophy (SMA); however, there is still no standard preclinical testing system for the disease. We previously generated type III-specific SMA model mice, which might be suitable for use as a preclinical therapeutic testing system for SMA. To establish such a system and test its applicability, we first created a testing protocol and then applied it as a means to investigate the use of valproic acid (VPA) as a possible treatment for SMA. These SMA mice revealed tail/ear/foot deformity, muscle atrophy, poorer motor performances, smaller compound muscle action potential and lower spinal motoneuron density at the age of 9 to 12 months in comparison with age-matched wild-type littermate mice. In addition, VPA attenuates motoneuron death, increases spinal SMN protein level and partially normalizes motor function in SMA mice. These results suggest that the testing protocol developed here is well suited for use as a standardized preclinical therapeutic testing system for SMA.",
keywords = "Animal model, Motoneuron disease, Neuronal degeneration, Phenotype, Spinal cord, Spinal muscular atrophy, Valproic acid",
author = "Tsai, {Li Kai} and Tsai, {Ming Shung} and Lin, {Tzer Bin} and Hwu, {Wuh Liang} and Hung Li",
year = "2006",
month = "11",
doi = "10.1016/j.nbd.2006.07.004",
language = "English",
volume = "24",
pages = "286--295",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Establishing a standardized therapeutic testing protocol for spinal muscular atrophy

AU - Tsai, Li Kai

AU - Tsai, Ming Shung

AU - Lin, Tzer Bin

AU - Hwu, Wuh Liang

AU - Li, Hung

PY - 2006/11

Y1 - 2006/11

N2 - Several mice models have been created for spinal muscular atrophy (SMA); however, there is still no standard preclinical testing system for the disease. We previously generated type III-specific SMA model mice, which might be suitable for use as a preclinical therapeutic testing system for SMA. To establish such a system and test its applicability, we first created a testing protocol and then applied it as a means to investigate the use of valproic acid (VPA) as a possible treatment for SMA. These SMA mice revealed tail/ear/foot deformity, muscle atrophy, poorer motor performances, smaller compound muscle action potential and lower spinal motoneuron density at the age of 9 to 12 months in comparison with age-matched wild-type littermate mice. In addition, VPA attenuates motoneuron death, increases spinal SMN protein level and partially normalizes motor function in SMA mice. These results suggest that the testing protocol developed here is well suited for use as a standardized preclinical therapeutic testing system for SMA.

AB - Several mice models have been created for spinal muscular atrophy (SMA); however, there is still no standard preclinical testing system for the disease. We previously generated type III-specific SMA model mice, which might be suitable for use as a preclinical therapeutic testing system for SMA. To establish such a system and test its applicability, we first created a testing protocol and then applied it as a means to investigate the use of valproic acid (VPA) as a possible treatment for SMA. These SMA mice revealed tail/ear/foot deformity, muscle atrophy, poorer motor performances, smaller compound muscle action potential and lower spinal motoneuron density at the age of 9 to 12 months in comparison with age-matched wild-type littermate mice. In addition, VPA attenuates motoneuron death, increases spinal SMN protein level and partially normalizes motor function in SMA mice. These results suggest that the testing protocol developed here is well suited for use as a standardized preclinical therapeutic testing system for SMA.

KW - Animal model

KW - Motoneuron disease

KW - Neuronal degeneration

KW - Phenotype

KW - Spinal cord

KW - Spinal muscular atrophy

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=33750001213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750001213&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2006.07.004

DO - 10.1016/j.nbd.2006.07.004

M3 - Article

C2 - 16952456

AN - SCOPUS:33750001213

VL - 24

SP - 286

EP - 295

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 2

ER -